<p>This is a summary of the European public assessment report (EPAR) for Corbilta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Corbilta.</p><p>For practical information about using Corbilta, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.</p></div>
Therapeutic Area (MeSH)
ATC Code
N04BA03
ATC Item
N/A
Pharmacotherapeutic Group
Anti-Parkinson drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| levodopa | N/A | levodopa |
| carbidopa | N/A | carbidopa |
| entacapone | N/A | entacapone |
EMA Name
Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)
Medicine Name
Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)
Aliases
N/ANo risk management plan link.
